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One strain of Bacillus subtilis and three antibiotic-
resistant strains of Staphylococcus aureus were employed to
determine the biological effects of everninomicin B (EvB), a
naturally occurring antibiotic produced by Micromonospora 
carbonacea (NRRL 2972) and M. carbonacea var. aurantiaca.
Minimum inhibitory concentration (MIC) of EvB for B. subtilis
was 1.2 x 10
-3 
pmole/m1 of EvB in glucose minimal broth and 2.6
x 10
-3 
wmole/m1 of EvB in nutrient broth. MIL values of EvB
for S. aureus were 3.25 x 10
-4 
,.,mole/m1 of EvB rol strains
resistant to penicillin or tetracycline and 6.5 x 10
-4 
umole/ml
of EvB for the aminoglycoside-resistant strain. The inhibitory
effect of EvB was found to be reversible for all concentrations
of EvB and all bacterial strains tested. The inhibitory effect
of EvB for B. subtilis was not dependent upon the initial con-
centration of cells nor the stage in the growth cycle at the
time the compound was introduced. The inhibitory effect was
dependent upon the initial concentration of cells for S. aureus.
Electron microscopy studies showed distinct morphological changes




In 1904 Ehrlich first described the feasibility of
using detoxified poisons (such as arsenic) to treat infections.
Since then researchers have been isolating and chemically
synthesizing many types of antimicrobial agents. In 1929
Fleming noticed that certain fungal metabolites would inhibit
bacterial growth. These fungal metabolites were termed
antibiotics (Rogers, 1969).
There are at least five modes of action by which anti-
biotics inhibit bacterial growth: (1) interruption of
necessary biochemical pathways, (2) inhibition of cell wall
synthesis, (3) inhibition of DNA or RNA synthesis, (4) in-
hibition of protein synthesis, and (5) physical damage to
the cell membrane (Richmond, 1966).
The first and most important antibiotic to be used was
penicillin. Penicillin is a naturally occurring antibiotic
produced by the fungus Penicillinm notatum and is one of many
antibiotics which inhibit peptidoglycan (cell wall) synthesis
(Park and Strominger, 1957). When the cell wall cannot be
synthesized the osmotically fragile protoplast will lyse
(Hancock and Fitz-James, 1964).
When antibiotics became commonly used, antibiotic-
resistant bacteria were selected for and became a major
medical problem. Antibiotic-resistant bacteria are those
bacteria with the genetic ability to resist the
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effects of an antibiotic (Kazuo et al., 1966). As the types
and strains of antibiotic-resistant bacteria increased, the
need for new and effective antibiotics became evident.
The genus Micromonospora produces five families of clin-
ically beneficial antibiotics (Table 1) and several anti-
biotics which have been isolated but not fully described
(Wagman and Weinstein, 1980). The aminoglycosides are the
most prominent of the antibiotics produced by Micromonospora.
The most clinically utilized aminoglycoside is gentamicin
which is a water-soluble antibiotic synthesized by M. purpurea
that has an unusually broad spectrum and can inhibit the
growth of antibiotic-resistant bacteria such as Proteus and
Pseudomonas (Wagman and Weinstein, 1980; Rosselet et al.,
1964; Oden et al., 1964). Its broad spectrum and low toxicity
for the host organism makes it an excellent antibiotic of
choice against gram-negative bacteria (Wagman and Weinstein,
1980). Gentamicin is known to bind irreversibly to the
305 ribosomal subunit which prevents translation during
protein synthesis (Petska, 1971).
The macrolides produced by Micromonspora can inhibit
bacterial growth only at an alkalinr pH and have mainly
a gram-positive spectrum (Wagman and Weinstein, 1980). The
macrolides inhibit bacterial growth by binding to the 50S
ribosomal subunit which prevents protein synthesis (Petska,
1971.
3
The ansamysins have been isolated from many species
of Micromonspora. Included in this family are the halo-
mycins and rifamicins (Weinstein et al., 1968). The ansa-
mycins prevent bacterial growth by inhibiting DNA-dependent
Rna polymerase thus preventing RNA synthesis. Mammalian
cells have been found to contain a RNA polymerase insen-
sitive to rifamicins , and the cells are not known to be
affected (Wehrli and Staehelin, 1971).
Actinomysins are peptide containing antibiotics with a
broad spectrum and a high degree of host toxicity (Reich,
1964). These antibiotics are the most potent and specific
inhibitiors of DNA-dependent RNA synthesis (Gellert et al.,
1965). The actinomycins have been used to study viral
replication and RNA function in prolaryotic and eukaryotic
systems (Reich et al., 1962). Kirk (1962) showed that in
mammalian systems, the actinomycins form reversible complexes
with DNA. The modes of action of the actinomycins are:
(1) prevention of DNA polymerization, (2) condensation of
chromatin, and (3) the loss of nuclear functions which
require the physical involvement of DNA (Reich et al.,
1962).
The everninomicins are a family of five related anti-
biotics designated A, B, C, D, and E. The are naturally
synthesized by M. carbonacea (NRRL 2972) and M. carbon-
acea var. aurantiaca (Wagman et al., 1965). The everninomicins
are composed of a dichloroseverinic acid complexed with a poly-
sacharide moeity (Herzog et al., 1965). Pharmacological
4
Table 1.
Antibiotics Produced by Micromonospora





























*Isolated but not yet- fully described.
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research with everninomicin D (EvD) showed that EvD had
extremely low host toxicity. In mice, EvD was shown to have
a 1,D50 of 3700 wg/kg when injected subcutaneously and 125 pg
when injected intravenously (Weinstein, et al., 1965). Their
study showed that when EvD was administered subcutaneously
t would provide in vivo protection for mice against lethal
strains of Staphylococcus aureus, Steptococcus pyogenes,
and Diplococcus pneumoniae. The amount needed for complete
protection against these bacterial infections was comparable
to penicillin G, methicillin, or oxacillin (Weinstein, et al.,
1965).
Black, et al., (1965) also researched the pharmacological
effect of EvD. In their study they utilized mice, dogs (beagle
hounds), and human beings. Their results showed that EvD
readily binds to human serum (94%). The rapidity of serum
binding by the antibiotic greatly diminished the antimicrobial
effect. In addition, subcutaneous administration resulted in
poor adsorption in muscle and the compound was excreted via
urinary and biliary routes. Other problems included finding
a suitable vehicle for injection, eliminating soreness at the
site of injection, and overcoming a distinct organic solvent
taste when administered orally.
Sanders and Sanders (1978) showed that EvB (which is
structurally similar to EvD) (Figure 1) had primarily a gram-
positive spectrum. Sensitive gram-negative bacteria are in the
genera Bacterioides, Hemophilus, and Neisseria. They also
Fiuro 1. Structure of Everninomicin B and Everninomicin D.
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showed that 73 strains of antibiotic-resistant gram-positive
bacteria were sensitive to EvB. Their results indicated
that there was no de novo resistance in any of the bacteria
tested. Because antibiotic-resistant bacteria are sensitive
to EvB and no resistance to the compound has been demonstrated,
it was suggested that EvB may have a novel mode of action
not previously described (Sanders and Sanders, 1978).
The objectives of this project were to (1) find the
minimum inhibitory concentration of EvB needed to inhibit
the growth of Bacillus subtilis W23 and three antibiotic-
resistant strains of Staphylococcus aureus, (2) determine
the reversibility of EvB-induced inhibition for Bacillus
subtilis W23 and three antibiotic-resistant strains of
Staphylococcus aureus, (3) determine if the effect of EvB
is dependent upon the initial concentration of cells of
actively growing cultures of Bacillus subtilis W23 and
penicillin-resistant Staphylococcus aureus, (4) determine
the effect of EvB on the viability of Bacillus subtilis W23
and penicillin-resistant Staphylococcus aureus and (5)
visualize any physical effects that EvB might have upon
the penicillin-resistant Staphylococcus aureus using
electron microscopy.
MATERIALS AND METHODS
Preparation of Everninomicin B for Bacterial Testing
The compound used in this study was everninomicin B
(EvB) originally obtained from the Schering Corporation,
Bloomfield, New Jersey. EvB, a white amorphous powder, was
kept in a screw-top vial and stored at 5°C. A stock solution
was prepared by placing 0.005 g of EvB and 0.5 ml of dimethyl-
sulfoxide (DMSO) into a sterile cap-all test tube. Sterile
distilled water (4.5 ml) was then added bringing the final
concentration of the solution to 0.63 wmole of EvB/ml. Stock
solutions of EvB were stored in cap-all test tubes at 5°C.
For experimentation appropriate dilutions were made of the
stock solutions.
Microorganisms
Bacillus subtilis W23 was obtained from the collection
of Dr. R. A. Brown, Western Kentucky University, Bowling
Green, Kentucky. Stock cultures of B. subtilis W23 were
maintained on glucose minimal agar slants at 50C.
Three strains of antibiotic-resistant Staphylococcus
aureus (wild strains) were clinically isolated at Greenview
Hospital, Bowling Green, Kentucky. The three antibiotic-
resistant strains employed were resistant to either penicillin,
tetracycline, or aminoglycosides. All three strains were found
to be gram-positive cocci in clusters, catalase positive,
8
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coagulase positive, and positive for mannitol fermentation.
The S. aureus strains were maintained on slants of brain
heart infusion agar at 5°C.
Bacterial Culture Media
Glucose minimal medium used in this study was composed
of 0.2% (w/v) NaC1, 0.2% (w/v) (NH4)2SO4, 0.32% (w/v) KH2PO4,
and 5% (w/v) glucose. The basal medium was prepared by
dissolving the NaC1, (NH4)2SO4, and KH2PO4 in deionized
distilled water and adjusting the pH to 7 with 1M KOH. The
basal medium was autoclaved at 121°C for 15 minutes.
Prior to use the basal medium was cooled to 25
o
C. A stock
solution of 10% (w/v) glucose and a mineral salts solution
were prepared and autoclaved separately. The mineral salts
solution was composed of 5% (w/v) MgSO4-7H20, 1% (w/v) MnSO4,
and 0.5% (w/v) CaC1
3 
in deionized distilled water. The basal
medium was supplemented with 0.1 ml mineral salts solution for
each 100 ml basal medium, and glucose added to a final con-
centration of 5% (v/v). Agar (DIFCO) was added to a final
concentration of 1.5% (w/v) for solid medium.
Brain heart infusion broth and brain heart infusion
agar (DIFCO) were used in the cultivation of S. aureus.
These media were made and sterilized in accordance with
label instructions.
Tube Dilution
The tube-dilution protocol was used to determine the
minimum inhibitory concentration (MIC) of EvB for the
bacteria tested. Twelve test tubes were used for each
10
bacterium tested. One ml of the appropriate breth Was
dispensed into each test tube except for the first test
tube. Two ml of appropriate broth containing 2.1 x 10
-2
umo1e/m1 of EvB were added to the first test tube. Serial
two-fold dilutions were made starting from 2.1 x 10
-2
 pmole
of EvB/m1 and ending with 1.05 x 10
-5 
umole of EvB/ml.
Bacteria from the stock cultures were inoculated into
9 ml of sterile broth and incubated for 18 hours at 36°C
on a rotary shaker. The broth culture was diluted 1:100 and
one ml was dispensed into each of the 12 test tubes. The
final concentrations of EvB after the addition of inoculum
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, 1.02 x 10
-5
, and 5.08 x 10
-6 
umole/ml, respectively.
The twelve test tubes were incubated for 13 hours at 36
o
C
on a rotary shaker and checked for visible growth.
highest dilution without visible growth was the MIC.
Reversibility was determined by removing 0.1-ml
The
aliquots
from all cultures showing no growth in each series and
inoculating them into 5 ml of sterile broth. These subcultures
were then incubated for 18 hours at 36°C on a rotary shaker.
After incubation the culture test tubes were checked for
visible growth. The highest dilution without visible growth
was considered to he the minimum bacteriocidal concentration
(MBC). If all the tubes showed visible growth, the effect of
the compound was considered to be reversible.
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Growth Experiments
Stock culture from an agar slant was loop inoculated into
9 ml of sterile broth and then incubated for 18 hours at 36
o
C
on a rotary shaker. These 18-hour cultures were then used
as inocula for further experimentation. For growth studies,
cells were inoculated into sterile test tubes (150 x 15 mm)
containing 5.0 ml sterile broth. Two growth controls were used
in all growth studies. Control A was made by adding only
sterile distilled water and control B by adding only DMSO
stock solution to the test tube. Added to the experimental
test tubes were appropriate concentrations of EvB. All test
tubes were inoculated to the desired optical density (between
0.06 and 0.08 units). Cell growth was monitored spectrophoto-
metrically at 540 nm using a Bausch and Lomb Spectronic 20 with
an 18-mm light path. Growth was monitored at hourly intervals
for 8 hours with a final reading at 24 hours.
Viability Determinations
Two side-arm flasks containing 25 ml of culture broth
were inoculated to an optical density of 0.10 units. To the
control flask, only sterile distilled water was added. EvB
was placed into the second side-arm flask at a concentration
of 1.3 x 10
-2 
'omole/ml. Both flasks were incubated at 16°C
until the optical density in the control flask reached 0.13
units. At designated times, one-ml aliquots from each side-
arm flask were placed into separate 99-ml dilution blanks
containing potassium phosphate buffer (pH 7.2). These dilution
blanks were then shaken (25 one-foot strokes in 7 seconds) and
12





. Each dilution was plated in duplicate using
the appropriate agar and incubated for 24 hours at 36°C.
Those plates showing between 30 and 300 colonies were counted
using a Quebec Colony Counter.
Electron Microscopy
A 0.5% (w/v) solution of formvar in chloroform was
prepared and allowed to stand at 25
o
C for 24 hours. A
microscope slide was immersed in the formvar solution, and
the chloroform was allowed to evaporate. Using a new razor
blade, a series of slices were made on the periphery of the
slide to initially release the formvar which was then loosened
by gently blowing on the slide. The loosened formvar was
then floated onto the surface of clean distilled water in a
500-ml culture dish. Copper grids were placed onto the floating
formvar sheet, and a pre-cleaned glass slide was placed over
the formvar sheet and grids. This slide was removed, inverted
and allowed to dry overnight at 25°C in a dust-free environment
Cells of S. aureus were treated with 1.3 x 10
-3 
.,Imole of
EVE per ml and allowed to incubate for 18 hours at 36
o
C on a
rotary shaker. Controls were grown in brain heart infusion
broth in which sterile distilled water was substituted for EvB
and incubated for 18 hours at 36
o
C on a rotary shaker. All
cells were centrifuged at 10,000 x g for 15 minutes in a
Sorval 55-1 centrifuge. The supernatant was discarded and
the cells washed three times in potassium phosphate buffer
13
(pH 7.2). After washing the cells were dropped onto formvar
grids with a pasteur pipet. A drop of 7% uranyl acetate was
placed onto the grids with the cells for negative staining.
The formvar grids were then blotted to dryness on cellulose
filter-paper disks, and the grids were observed with a Zeiss
EM 9S-2 electron microscope.
RESULTS
Minimum Inhibitory Concentrations
The MIC of EvB when using Bacillus subtilis W23 grown
in glucose minimal broth was 1.3 x 10
-3 
omole of EvB per ml.
The MIC of EvB when B. subtilis W23 was grown in nutrient
broth was 2.6 x 10
-3 
,:mole of EvB per ml. This represented
a two-fold increase in MIC (Table 2) when the media were
changed.
The MIC of EvB for the three antibiotic-resistant strains
of S. aureus was 3.25 x 10
-4 
. mole of EvB per ml for the
penicillin-resistant strain and the tetracycline-resistant
strain and 6.5 x 10
-4
mole of EvB per ml for the strain
of S. aureus resistant to aminoglycosides (Table 2).
Reversibilities
The reversibility of EvB-induced inhibition was determined
for all bacterial strains used in this study. B. subtilis W23
was subcultured into fresh medium from all negative tubes. For
cells grown in glucose minimal broth this represented con-
centrations of EvB starting from 1.3 x 10
-3 
to 1.05 x 10
-2
omole/ml. When grown in nutrient broth, the concentrations
of EvB from the negative growth cultures ranged from 2.6 x 10
-3
to 1.05 x 10
-2 
omole/ml. The results indicated that the
effect of the compound was reversible for B. subtilis W23 for
all concentrations of EvB tested (Table 3).
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TABLE 2
MINIMUM INHIBITORY CONCENTRATION DETERMINATIONS FOR
BACILLUS SUBTILIS W23 AND THREE ANTIBIOTIC-





P-R T-R A-R RS GMMB
1.05 x 10
-2 c_ _ _ _ _
5.20 x 10
-3 _ _ _ _ _
2.60 x 10
-3 _ _ _ _ _
1.30 x 10
-3





- - - + +
3.25 x 10
-4 _ _ + + +
1.63 x 10
-4
+ + + + +
8.13 x 10
-5
+ + + + +
4.10 x 10
-5
+ + + + +
2.03 x 10
-5
+ + + + +
1.02 x 10
-5
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5.08 x 10
-6









NB: B. subtilis grown in nutrient broth






REVERSIBILITY OF EVERNINOMICIN-B-INDUCED INHIBITION
FOR BACILLUS SUBTILIS W23 AND THREE ANTIBIOTIC-
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NB: B. subtilis grown in nutrient broth




All negative cultures from antibiotic-resistant
S. aureus were subcultured into fresh brain heart infusion
broth. The concentrations of EvB of the negative growth
cultures ranged from 3.25 x 10
-4 
to 1.05 x 10
-2 
illio1e/m1
for the penicillin- and tetracycline-resistant strains and
6.5 x 10
-4 
to 1.05 x 10
-2 
fllole/m1 for the strain resistant
to aminoglycosides. The results indicate that the effect
of the compound was reversible for all concentrations
of EvB tested for the three antibiotic-resistant strains
(Table 3).
Growth Studies
B. subtilis W23 was inoculated into glucose minimal
broth with EvB at a concentration of 6.5 x 10
-3 
,mole/m1
which represented a five-fold increase of the MIC value. There
was 100% growth inhibition after 24 hours (Figure 2).
Penicillin-resistant S. aureus was grown in brain heart
infusion broth with EvB added at concentrations of 1.3 x 10
-3
and 6.5 x 10
-3 
umole/m1. Both concentrations of EvB had the
same effect, 66% growth inhibition when compared to the
controls (Figure 3).
After the initial growth studies were performed, the
stability of compound was investigated to determine if the
effects of incubation (i.e. shaking, temperature, degradation
of compound due to media, or incubation time) could result
in the loss of biological activity of EvB. Three series of
test tubes containing glucose minimal broth plus 1.3 x 10
-2
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Figure 2. Effect of Everninomicin B on growth of Bacillus
subtilis W23 (e), glucose minimal broth controls




Figure 3. Effect of Everninomicin B on the growth of penicillin-
resistant Staphylococcus aureus (10), brain hear
infusion controls (i), 6.5 -:i-10-J and 1.3 x 10










umole/ml of EvB and three control series were incubated cell-
free on a rotary shaker at 36°C for 24, 48, and 72 hours.
After each 24-hour cell-free incubation period, B. subtilis 
W23 was inoculated into the EvB and control series which were
then incubated for an additional 24 hours at 36°C on a rotary
shaker. The results showed that after 72 hours of standard
cell-free incubation, EvB did not lose its ability to inhibit
the growth of B. subtilis W23 (Figure 4).
Studies of the effect of initial inoculum size were
used to determine if the inhibitory effect of EvB was
dependent upon the initial concentration of cells in the
culture medium. B. subtilis W23 was inoculated into four
series of test tubes containing glucose minimal broth and
EvB at a concentration of 6.5 x 10
-3 
umole/ml. The initial
optical densities in the four series were 0.2, 0.2, 0.3, and
0.4 units. Control test tubes were run for each series and
adjusted to comparable optical densities. B. subtilis W23
showed 100% inhibition after 24 hours at all optical densities
employed (Figure 5).
The effect of initial inocula size was determined using
penicillin-resistant S. aureus. All growth conditions were
kept similar to the previous experiment except that brain
heart infusion medium was used. At an initial optical
density of 0.1 units S. aureus treated with EvB showed 50%
growth inhibition after 24 hours. When S. aureus was inoculated
to an initial optical density of 0.2 units the treated cells
21
Figure 4. Effect of growth conditions on the stability of
Everninomicin B after 72 hours cell-free incubation
(40)•, glucose minimal broth controls; (II), 1.3 x
10-z umole/ml of EvB in glucose minimal broth.

Figure 5. Effect of initial inoculum size on Everninomicin B
induced growth inhibition of Bacillus subtilis W23.
A: initial optical density 0.1 OD units, B: initial
optical density 0.2 OD units, C: initial optical
density 0.3 units, D: initial optical density 0.4 OD
units. (0), glucose minimal broth controls; (II),

















































































































showed approximately 15% growth inhibition after 24 hours.
At initial optical densities of 0.3 and 0.4 units there was
no EvB-induced inhibition after 24 hours for treated cells
of S. aureus. These results indicated that the effect of
EvB was dependent upon initial concentration of cells for
S. aureus (Figure 6).
Time-of-addition studies were performed to determine if
EvB had more or less of an inhibitory effect when added at
different times during the incubation period. B. subtilis
W23 was inoculated into glucose minimal broth at an optical
density of 0.08 units and incubated on a rotary shaker at 36°C
until a change in optical density was detected. EvB was added
at a concentration of 6.5 x 10
-3 
.,:mole/ml to the actively
growing cultures at 2-hour intervals. As the compound was
added, sterile distilled water and DMSO were added to the
controls. The results showed that when EvB was added at any
time during the incubation period there was 100% inhibition
of growth (Figure 7).
Time-of-addition studies were performed using penicillin-
resistant S. aureus. The growth conditions were similar to
the previous experiment except that shorter addition times
were used, and brain heart infusion broth was the medium of
choice. These studies showed that when EvB was added initially
there was 50t growth inhibition after 24 hours and no inhibition
after 48 hours. When the compound was added after one hour
to actively growing cultures, there was also 50% growth
Figure 6. Effect of initial inoculum size on Everninomicin B
induced growth inhibition of penicillin-resistant
Staphylococcus aureus. A: initial optical density
0.1 OD units, B: initial optical density 0.2 OD
units, C: initial optical density 0.3 OD units,
D: initial optical density 0.4 OD units.._ 3 (0),
glucose minimal broth controls; 6.5 x 10 :Imole/m1
of EvB in brain heart infusion brothll.
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Figure 7. Effect of time of addition of Everninomicin B induced
inhibition of Bacillus subtilis W23. A: compound
added at time 0, B: compound added after 2 hours
incubation, C: compound added after 4 hours incuba-
tion, D: compound added after 6 hours incubation._3
(40) glucose minimal broth controls; (IV 6.5 x 10


































































































































inhibition and no inhibition after 48 hours. When EvB was
added to approximately two-hour actively growing cultures
there was 33% inhibition of growth and no inhibition after
48 hours. When the compound was added to S. aureus which had
been actively growing for 21/2 hours there was 20% growth
inhibition after 24 hours and no inhibition after 48 hours.
These results indicated that for S. aureus the effect of EvB-
induced growth inhibition was dependent upon the time of
addition (Figure 8).
Viability Determinations
Viability determinations were used to determine if EvB-
induced inhibition was bacteriostatic or bacteriocidal. B.
subtilis W23 was grown in glucose minimal broth and plated
on glucose minimal agar. The results showed that after a
90-minute incubation period there was no increase in colony
forming units/ml (CFU/ml), which indicated that EvB was
bacteriostatic for B. subtilis W23 (Figure 9).
Similar viability determinations as described previously
were performed on the penicillin-resistant S. aureus except
that this strain was grown in brain heart infusion broth and
plated on brain heart infusion agar. After a 90-minute
incubation period there was no increase in CFU/ml which
indicated that for S. aureus the effect of EvB was bacterio-
static (Figure 10).
Figure 8. Effect of time of addition on Everninomicin B
induced growth inhibition of penicillin-resistant
Staphylococcus aureus. A: compound added at time
0, B: compound added after 1.0 hours, C: compound
added after 2.25 hours, D: compound added after
2.5 hours. (II), brain hart infusion broth
controls: (II) 6.5 x 10-'omole/m1 of EvB in brain
heart infusion broth.

Figure 9. Effect of Fverninomicin B on the viability of
Bacillus subtilis W23. (0), glusose minimal
medium controls; (l). 1.3 x 10 omo1e/m1 of




















Figure 10. Effect of Everninomicin B on the viability of
penicillin-resistant Staphylococcus aureus.
(410), brain heart infusion medium controls; (I),


















When control cells of penicillin-resistant S. aureus
were examined with an electron microscope, the cells had
shown typical cluster formation and uniform morphology
(Figure 11). When the penicillin-resistant S. aureus was
treated with 1.3 x 10
-3 
Llmole of FvB per ml and incubated
for 18 hours on a rotary shaker at 36°C it was noted that the
treated cells showed marked pleomorphism, and lysis of some
of the treated cells occurred (Figure 12).
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Figure 11. Electron micrograph of untreated penicillin-
resistant Staphylococcus aureus. Note regular




Figure 12. Electron micrograph of Everninomicin B treated
penicillin-resistant Staphylococcus aureus. S.
aureus was treated with 1.3 x 10-3 umole/ml of
EvB for 18 hours at 36°C. Note pleomorphic cells




Micromonospora carbonacea (NRRL 2972) and M. carbonacea
var. aurantiaca have been demonstrated to produce a complex
of antibiotics known as the everninomicins (Wagman, et al.,
1965). Of the five everninomicins complexes, EvD is produced
in the greatest amount (Herzog, et al., 1965); because
of this most of the pharmacological research has been done
with EvD (Weinstein, et al., 1964; Black, et al., 1965).
Herzog, et al. (1965) showed that EvD and EvB are structurally
related. Although EvB has primarily a gram-1-„ositive spectrum
(Black, et al., 1965), Sanders and Sanders (1978) showed that
antibiotic-resistant bacteria are sensitive to EvB. They
also demonstrated that there was no de novo resistance which
suggested that EvB may have a novel mode of action. More
research is needed to elucidate possible modes of action of
EvB.
In this study the tube-dilution protocol showed that
the bacterial strains tested were sensitive to the inhibitory
effects of EvB. This was reflected by the fact that EvB
had low MIC values for all bacterial strains tested.
When B. subtilis was grown in nutrient broth there was
a two-fold increase in the MIC value. It was possible that
the biological effects of EvB in nutrient broth were decreased
as the natural complex of nutrients in the media increased
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(Foster and Pittillo, 1952). The MIC values for the three
antibiotic-resistant strains of S. aureus agree with the
results of Sanders and Sanders (1978).
Tube-dilution reversibilities showed that the inhibitory
effect was reversible for B. subtilis W23 with concentrations
of EvB ranging from 1.3 x 10
-3 
to 1.05 x 10
-2 
omole/ml when
B. subtilis was grown in glucose minimal broth and 2.6 x
10
-3 
to 1.05 x 10
-2 
1„mole/ml when B. subtilis was grown in
nutrient broth. Tube-dilution reversiblities for three
antibiotic-resistant strains of S. aureus showed that the
inhibitory effect of EvB was reversible with concentrations
ranging from 3.25 x 10
-4 
to 1.05 x 10
-2 
 mole/m1 for the
strains resistant to penicillin or tetracycline and 6.5 x
-4 




umole/ml for S. aureus resistant to
aminoglycosides.
In growth studies using B. subtilis W23 and S. aureus_
the concentration of EvB used was 6.5 x 10
-3
pmole/ml which
represented a five-fold increase in the MIC value for B. subtilis
and a twenty-fold increase over the MIC value for S. aureus.
At this concentration the inhibitory effect of EvB against
B. subtilis W23 was not dependent upon the initial concentra-
tion of cells nor was it dependent upon when the compound was
added to the actively growing cultures. The effect of EvB
on penicillin-resistant S. aureus was dependent upon the initial
concentration of cells as well as upon the time of addition
of EvB. These results indicate that for S. aureus the higher
the concentration of cells (either actively growing or non-
growing cells) the less inhibition of growth was detected.
Viability determinations for B. subtilis and S. aureus
showed that after a 90-minute incubation period there was
no increase in CFU/ml in the treated cultures. The results
of the viability determinations and reversibility studies
indicated that EvB was bacteriostatic.
A probable explanation for the differences between
the results of B. subtilis and S. aureus was the difference
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in the media. B. subtilis, often used in antibiotic research,
can be grown in minimal media. S. aureus can only be grown
in complex media which could reduce the inhibitory effect of
the compound on bacterial growth (Foster and Pittillo, 1952).
Electron microscopy showed that when cells of S. aureus
were exposed to EvB and compared to untreated cells there
were distinct morphological changes in the untreated cells.
These changes included marked pleomorphism and lysis. It
could not be determined from this study if the lysis of the
treated cells was due to the actual effect of the compound
or if cellular lysis was due to the physical effects of the
vacuum when the cells were placed into the electron microscope.
In evaluating EvB for possible use as a clinically
significant antibiotic, more research is needed to elucidate
its exact mode of action, a suitable vehicle for injection
must be found, and an analogue which will not bind readily to
human serum should be synthesized. Further alternative
36
research should include the possible use of EvB in selective
media, or as a preservative of foodstuffs because of its
low host toxicity.
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